A new approach to disease-modifying drug trials in Parkinson's disease

Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

Abstract

Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.

Detaljer

Författare
  • Roger A. Barker
  • Mark Stacy
  • Patrik Brundin
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Neurovetenskaper
Originalspråkengelska
Sidor (från-till)2364-2365
TidskriftJournal of Clinical Investigation
Volym123
Utgivningsnummer6
StatusPublished - 2013
PublikationskategoriForskning
Peer review utfördNej

Nedladdningar

Ingen tillgänglig data